Brooke Day died after her backpack became entangled in a gondola lift at Tsugaike Mountain Resort, leading to a fatal cardiac arrest, highlighting rare but critical safety concerns.
A partial government shutdown triggers furloughs, the Grammys become a platform for political statements, and nationwide protests over immigration policy unfold amid a severe winter storm's aftermath.
A new bilateral trade agreement between the United States and Guatemala aims to eliminate tariffs and streamline preferential treatment for textiles and apparel, a move hailed by U.S. industry leaders as a strategic step to reinforce regional manufacturing networks and counter Asian dominance.
For those on a fixed income, inflation isn't just an economic indicator—it's a direct assault on financial security. Experts warn that failing to plan for rising costs can halve a retiree's purchasing power over decades. Here’s a strategic guide to building a resilient portfolio.
Amid a mixed market backdrop, penny stocks are drawing renewed attention for their growth potential. We analyze three standout picks, led by financial services firm Siebert Financial, highlighting their financial health and strategic moves in a volatile landscape.
The global payments giant reported a 15% surge in net revenue and processed a record 69.4 billion transactions in its fiscal first quarter, signaling resilient consumer confidence and a rebound from previous quarters.
Former President Donald Trump has announced Kevin Warsh, a former Federal Reserve governor and economic advisor, as his pick to lead the central bank. The nomination comes as incumbent Chair Jerome Powell faces a federal investigation related to his congressional testimony.
Analysts at Piper Sandler have increased their price target for Permian Basin-focused producer Diamondback Energy (FANG) to $218, maintaining an Overweight rating. The move comes as the firm anticipates solid Q4 results for gas-focused companies, while oil producers navigate a tougher pricing environment.
Insurance brokerage giant Brown & Brown sees a key price target cut to $81 following its fourth-quarter earnings, which revealed robust fee growth but concerns over slowing organic revenue expansion.
Barclays raises its price target on NorthWestern Energy Group (NWE) to $62, citing solid quarterly performance and strategic moves, including a pending merger with Black Hills Corporation, as the regulated utility reaffirms its long-term growth outlook.
TD Cowen raises Prudential Financial's price target to $113, maintaining a 'Hold' rating, as the insurer grapples with a misconduct scandal at its Japan life insurance unit affecting nearly 500 customers.
Wells Fargo lowered its price target on UnitedHealth Group (UNH) following its Q4 report and a disappointing Medicare rate proposal from regulators, highlighting pressures on the healthcare giant's key growth engine.
Amid a mixed market landscape, corporate insiders are placing significant bets on select small-cap stocks. We analyze three companies where recent insider buying and strategic moves signal potential value, despite broader economic headwinds.
Amidst a mixed economic backdrop, we spotlight three U.S. tech companies—Rumble, Daktronics, and Sandisk—whose strategic initiatives and robust growth projections set them apart for investors looking beyond near-term turbulence.
The all-stock deal creates a top-tier independent producer focused on the Permian Basin, with Beth McDonald at the helm aiming to unlock significant synergies and shareholder returns.
Essar Oil and Gas Exploration & Production (EOGEPL) is injecting $100 million into its flagship Raniganj East CBM block in West Bengal, aiming to scale up domestic natural gas production and explore shale potential in a bid to reduce India's import reliance.
IPSASB unveils the world's first dedicated climate reporting standard for governments and public bodies, mandating disclosures from 2028 to illuminate financial risks and opportunities.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
Nominee Kevin Warsh's desire to aggressively shrink the Federal Reserve's multi-trillion dollar holdings collides with a financial system now structurally dependent on ample liquidity, making rapid contraction a high-risk endeavor, analysts say.
